114 related articles for article (PubMed ID: 15902694)
1. SEPT9_v4 expression induces morphological change, increased motility and disturbed polarity.
Chacko AD; Hyland PL; McDade SS; Hamilton PW; Russell SH; Hall PA
J Pathol; 2005 Aug; 206(4):458-65. PubMed ID: 15902694
[TBL] [Abstract][Full Text] [Related]
2. Properties of SEPT9 isoforms and the requirement for GTP binding.
Robertson C; Church SW; Nagar HA; Price J; Hall PA; Russell SE
J Pathol; 2004 May; 203(1):519-27. PubMed ID: 15095474
[TBL] [Abstract][Full Text] [Related]
3. Translational control of SEPT9 isoforms is perturbed in disease.
McDade SS; Hall PA; Russell SE
Hum Mol Genet; 2007 Apr; 16(7):742-52. PubMed ID: 17468182
[TBL] [Abstract][Full Text] [Related]
4. High SEPT9_v1 expression in human breast cancer cells is associated with oncogenic phenotypes.
Gonzalez ME; Peterson EA; Privette LM; Loffreda-Wren JL; Kalikin LM; Petty EM
Cancer Res; 2007 Sep; 67(18):8554-64. PubMed ID: 17875694
[TBL] [Abstract][Full Text] [Related]
5. SEPT9_i1 regulates human breast cancer cell motility through cytoskeletal and RhoA/FAK signaling pathway regulation.
Zeng Y; Cao Y; Liu L; Zhao J; Zhang T; Xiao L; Jia M; Tian Q; Yu H; Chen S; Cai Y
Cell Death Dis; 2019 Sep; 10(10):720. PubMed ID: 31558699
[TBL] [Abstract][Full Text] [Related]
6. Septin 9_i2 is downregulated in tumors, impairs cancer cell migration and alters subnuclear actin filaments.
Verdier-Pinard P; Salaun D; Bouguenina H; Shimada S; Pophillat M; Audebert S; Agavnian E; Coslet S; Charafe-Jauffret E; Tachibana T; Badache A
Sci Rep; 2017 Mar; 7():44976. PubMed ID: 28338090
[TBL] [Abstract][Full Text] [Related]
7. Multimodality expression profiling shows SEPT9 to be overexpressed in a wide range of human tumours.
Scott M; Hyland PL; McGregor G; Hillan KJ; Russell SE; Hall PA
Oncogene; 2005 Jul; 24(29):4688-700. PubMed ID: 15782116
[TBL] [Abstract][Full Text] [Related]
8. Insights into animal septins using recombinant human septin octamers with distinct SEPT9 isoforms.
Iv F; Martins CS; Castro-Linares G; Taveneau C; Barbier P; Verdier-Pinard P; Camoin L; Audebert S; Tsai FC; Ramond L; Llewellyn A; Belhabib M; Nakazawa K; Di Cicco A; Vincentelli R; Wenger J; Cabantous S; Koenderink GH; Bertin A; Mavrakis M
J Cell Sci; 2021 Aug; 134(15):. PubMed ID: 34350965
[TBL] [Abstract][Full Text] [Related]
9. Septin 9 isoform expression, localization and epigenetic changes during human and mouse breast cancer progression.
Connolly D; Yang Z; Castaldi M; Simmons N; Oktay MH; Coniglio S; Fazzari MJ; Verdier-Pinard P; Montagna C
Breast Cancer Res; 2011 Aug; 13(4):R76. PubMed ID: 21831286
[TBL] [Abstract][Full Text] [Related]
10. Altered patterns of transcription of the septin gene, SEPT9, in ovarian tumorigenesis.
Scott M; McCluggage WG; Hillan KJ; Hall PA; Russell SE
Int J Cancer; 2006 Mar; 118(5):1325-9. PubMed ID: 16161048
[TBL] [Abstract][Full Text] [Related]
11. Septin 9 amplification and isoform-specific expression in peritumoral and tumor breast tissue.
Connolly D; Hoang HG; Adler E; Tazearslan C; Simmons N; Bernard VV; Castaldi M; Oktay MH; Montagna C
Biol Chem; 2014 Feb; 395(2):157-67. PubMed ID: 24127542
[TBL] [Abstract][Full Text] [Related]
12. Targeted knockdown of SEPT9_v1 inhibits tumor growth and angiogenesis of human prostate cancer cells concomitant with disruption of hypoxia-inducible factor-1 pathway.
Amir S; Golan M; Mabjeesh NJ
Mol Cancer Res; 2010 May; 8(5):643-52. PubMed ID: 20407014
[TBL] [Abstract][Full Text] [Related]
13. Expression of the SEPT9_i4 isoform confers resistance to microtubule-interacting drugs.
Chacko AD; McDade SS; Chanduloy S; Church SW; Kennedy R; Price J; Hall PA; Russell SE
Cell Oncol (Dordr); 2012 Apr; 35(2):85-93. PubMed ID: 22278362
[TBL] [Abstract][Full Text] [Related]
14. SEPT9 sequence alternations causing hereditary neuralgic amyotrophy are associated with altered interactions with SEPT4/SEPT11 and resistance to Rho/Rhotekin-signaling.
Sudo K; Ito H; Iwamoto I; Morishita R; Asano T; Nagata K
Hum Mutat; 2007 Oct; 28(10):1005-13. PubMed ID: 17546647
[TBL] [Abstract][Full Text] [Related]
15. Up-regulation of SEPT9_v1 stabilizes c-Jun-N-terminal kinase and contributes to its pro-proliferative activity in mammary epithelial cells.
Gonzalez ME; Makarova O; Peterson EA; Privette LM; Petty EM
Cell Signal; 2009 Apr; 21(4):477-87. PubMed ID: 19071215
[TBL] [Abstract][Full Text] [Related]
16. SEPT9_V1 protein expression is associated with human cancer cell resistance to microtubule-disrupting agents.
Amir S; Mabjeesh NJ
Cancer Biol Ther; 2007 Dec; 6(12):1926-31. PubMed ID: 18075300
[TBL] [Abstract][Full Text] [Related]
17. The concerted action of SEPT9 and EPLIN modulates the adhesion and migration of human fibroblasts.
Hecht M; Alber N; Marhoffer P; Johnsson N; Gronemeyer T
Life Sci Alliance; 2024 Jul; 7(7):. PubMed ID: 38719752
[TBL] [Abstract][Full Text] [Related]
18. Proteomic profiling of the oncogenic septin 9 reveals isoform-specific interactions in breast cancer cells.
Devlin L; Okletey J; Perkins G; Bowen JR; Nakos K; Montagna C; Spiliotis ET
Proteomics; 2021 Oct; 21(19):e2100155. PubMed ID: 34409731
[TBL] [Abstract][Full Text] [Related]
19. Septin 9 Exhibits Polymorphic Binding to F-Actin and Inhibits Myosin and Cofilin Activity.
Smith C; Dolat L; Angelis D; Forgacs E; Spiliotis ET; Galkin VE
J Mol Biol; 2015 Oct; 427(20):3273-3284. PubMed ID: 26297986
[TBL] [Abstract][Full Text] [Related]
20. The pathobiology of the septin gene family.
Hall PA; Russell SE
J Pathol; 2004 Nov; 204(4):489-505. PubMed ID: 15495264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
